Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Amprion and Prema Cognition have formed a collaboration pairing a 10–15 minute digital memory assessment with seed amplification biomarker assays for neurodegenerative disease. The digital test measures memory precision rather than simple recall, aiming to flag individuals with subjective cognitive decline who score normally on conventional screening and may warrant confirmatory molecular testing. No performance data, timeline, or cost structure has been disclosed.
John Beard, who led the WHO's World Report on Ageing and Health, argues that function — not diagnosis count — is the more accurate measure of how a person is aging. Intrinsic capacity assesses five domains: cognition, mobility, psychological resilience, sensory function and vitality, and can be tracked incrementally from midlife rather than waiting decades for disease endpoints. Cohort data from England and China indicate newer generations reach a higher functional peak rather than declining more slowly, suggesting interventions can raise the ceiling, not only slow the descent.
Renue by Science has opened a decentralized research platform allowing adults to enroll in Institutional Review Board-reviewed studies from home, contributing questionnaire responses, health data and wearable device readings across baseline, intervention and optional washout periods. Planned study topics include supplements, sleep and healthy aging, with findings intended for research summaries, scientific presentations or peer-reviewed publication. The model addresses a persistent gap in the supplement sector, where consumer products are rarely subjected to structured outcome tracking.
A post-hoc analysis of Longeveron's 49-person Phase 2a CLEAR MIND trial used free water MRI to assess neuroinflammation in Alzheimer's patients treated with laromestrocel, an allogeneic mesenchymal stem cell product. Reduced inflammatory signal in the left hippocampus and temporal-parietal cortex tracked with less atrophy, better cognitive scores, and lower plasma neurogranin. The findings are exploratory, unreviewed, and hypothesis-generating rather than confirmatory.
Tenvie Therapeutics has dosed the first participant in a Phase 1 trial of TNV313, an orally administered small molecule designed to inhibit NLRP3 and cross the blood-brain barrier. The ascending-dose study in healthy volunteers will assess safety, pharmacokinetics, central nervous system distribution and exploratory pharmacodynamic biomarkers, with preliminary data expected in the first half of 2027. NLRP3-driven inflammatory signaling is implicated in neurodegenerative, cardiometabolic and ophthalmic disease, making brain-accessible inhibition a target of interest for age-related decline.
Inmune Bio and Quantum Computing Inc. will apply quantum optimization, AI and data analytics to clinical datasets spanning preclinical work through four trials of XPro, an investigational selective inhibitor of soluble tumor necrosis factor. The objective is to identify additional diseases and biomarkers driven by the same inflammatory biology the drug targets, beginning with rare diseases that permit smaller, faster trials. Outputs from the Dirac-3S machine will be benchmarked against conventional statistical and machine learning approaches.
Diagnostic Imaging Centers of Texas is adding VoxNeuro's FDA-cleared EEG-based Cognitive Function Neuroimaging to its MRI and CT services, pairing structural scans with an objective measure of how the brain responds during attention and memory tasks. The event-related potential analysis is completed in a single visit and cleared for prescription use in adults aged 18 to 70, without providing diagnosis or clinical interpretation. No outcome data has been published on whether the test alters treatment decisions or recovery trajectories.
A Lancet Neurology study measuring 130 blood proteins across 2,385 samples from patients receiving lecanemab found that the markers tracking amyloid clearance were largely distinct from those tracking later cognitive decline. Brain-derived tau variants outperformed peripherally produced forms in distinguishing treated patients from untreated controls. The findings point toward multi-marker blood profiling as a route to understanding why identical diagnoses and identical therapies produce divergent outcomes.
Mighty Therapeutics and the University of Washington received $1 million as a Milestone 2 Awardee in the XPRIZE Healthspan competition for pilot work on elamipretide, a peptide that binds cardiolipin to support mitochondrial structure and function. The pilot results have not been disclosed; the team describes them as feasibility data intended to inform a randomized, placebo-controlled trial of muscle, cognitive and immune function in older adults. Elamipretide already holds FDA approval for Barth syndrome, making it one of the few mitochondria-directed therapies with a regulatory track record.
The Rhode Island Life Science Hub and Cognito Therapeutics have established the Rhode Island Brain Health Collaboratory, a statewide platform to evaluate and deploy Cognito's Spectris neuromodulation technology across health systems and research institutions. It is the third such regional collaboratory in Cognito's network, following partnerships in West Virginia and with Ochsner Health. The company states that Spectris AD holds FDA Breakthrough Device designation and that pivotal HOPE trial results are expected later in 2026.
A 10-year population-based cohort study examined how socioeconomic conditions in early life relate to cognitive reserve and the rate of cognitive decline in later adulthood. Early-life disadvantage is associated with lower cognitive reserve and less favorable aging trajectories, while reserve accumulated across the lifespan appears to modify that association. Cognitive aging is shaped by exposures that begin decades before symptoms become measurable.
Researchers examined whether polygenic scores for human longevity correspond to structural brain measures on MRI in a population-based cohort of 70-year-olds. The work tests whether inherited predisposition to exceptional lifespan is visible in the aging brain decades before survival outcomes are known, positioning neuroimaging as a possible intermediate marker of biological aging.